Patents Examined by Stephen Rawlings
-
Patent number: 10428153Abstract: According to one aspect there is provided An isolated human antibody molecule which binds to the TSHR and which reduces ligand-induced stimulation of the TSHR but has no effect on TSHR constitutive activity wherein the isolated human antibody molecule has the characteristic of patient serum TSHR autoantibodies of inhibiting TSH and M22 binding to the TSHR.Type: GrantFiled: July 2, 2015Date of Patent: October 1, 2019Assignee: RSR Ltd.Inventors: Bernard Rees-Smith, Jane Sanders, Jadwiga Furmaniak
-
Patent number: 10053504Abstract: The invention provides compositions comprising SPARC binding ScFv and its use.Type: GrantFiled: April 19, 2016Date of Patent: August 21, 2018Assignee: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Patent number: 10047159Abstract: The present invention provides a method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of CD3 and a second binding domain capable of binding to the extracellular do main cell surface antigens with a high molecular weight extracellular domain. Moreover, the invention provides bispecific single chain antibodies produced by the use of the method of the invention, nucleic acid molecules encoding these antibodies, vectors comprising such nucleic acid molecules and methods for the production of the antibodies. Furthermore, the invention provides pharmaceutical compositions comprising bispecific single chain antibodies of the invention, medical uses of the same and methods for the treatment of diseases comprising the administration of bispecific single chain antibodies of the invention.Type: GrantFiled: January 8, 2016Date of Patent: August 14, 2018Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Claudia Blümel, Roman Kischel
-
Patent number: 10047131Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 30, 2016Date of Patent: August 14, 2018Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10040862Abstract: Humanized or chimeric anti-CD99 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD99, and find use in various therapeutic methods. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD99 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.Type: GrantFiled: April 17, 2015Date of Patent: August 7, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jie Liu, Ronald Levy, Ravindra Majeti
-
Patent number: 10035856Abstract: A targeted T-cell engaging agent for treating a condition characterized by the presence of unwanted cells includes (a) a targeting moiety that is capable of targeting the unwanted cells; (b) a first T-cell engaging domain capable of T-cell engaging activity when binding a second T-cell engaging domain, wherein the second T-cell engaging domain is not part of the agent; (c) at least one inert binding partner capable of binding to the first T-cell engaging domain such that the first T-cell engaging domain does not bind to the second T-cell engaging domain unless the inert binding partner is removed; and (d) at least one cleavage site separating the first T-cell engaging domain and the inert binding partner, wherein the cleavage site is: (i) cleaved by an enzyme expressed by the unwanted cells; (ii) cleaved through a pH-sensitive cleavage reaction inside the unwanted cell; (iii) cleaved by a complement-dependent cleavage reaction; or (iv) cleaved by a protease that is colocalized to the unwanted cell by a targetType: GrantFiled: November 18, 2016Date of Patent: July 31, 2018Assignee: Revitope LimitedInventor: Mark Cobbold
-
Patent number: 10011858Abstract: In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies.Type: GrantFiled: March 31, 2006Date of Patent: July 3, 2018Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Tsunoda
-
Patent number: 10010592Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumor antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of cancer or tumor diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a tumor antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.Type: GrantFiled: February 15, 2013Date of Patent: July 3, 2018Assignee: CureVac AGInventors: Andreas Thess, Thomas Schlake, Jochen Probst
-
Patent number: 9993540Abstract: A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has brain cancer. A method of treating a patient who has brain cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the brain cancer.Type: GrantFiled: June 30, 2017Date of Patent: June 12, 2018Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Patent number: 9951145Abstract: Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein.Type: GrantFiled: November 27, 2013Date of Patent: April 24, 2018Assignee: AJOU UNIVERSITY INDUSTRY—ACADEMIC COOPERATION FOUNDATIONInventors: Yong Sung Kim, Hye Ji Choi, Eun Sil Sung
-
Patent number: 9951142Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: GrantFiled: February 25, 2015Date of Patent: April 24, 2018Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 9903872Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of HCC, glioblastoma and lung cancer, for monitoring the effectiveness of HCC, glioblastoma and lung cancer treatment, and for drug development.Type: GrantFiled: September 10, 2015Date of Patent: February 27, 2018Assignee: Oxford BioTherapeutics, Ltd.Inventor: Christian Rohlff
-
Patent number: 9902775Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.Type: GrantFiled: December 10, 2013Date of Patent: February 27, 2018Assignee: Biogen MA Inc.Inventors: Justin A. Caravella, Ellen A. Garber Stark, Dania Mounir Rabah, Frederick R. Taylor
-
Patent number: 9884098Abstract: Compositions and methods for immunization against human breast cancer are disclosed. In one embodiment the multivalent antigenic composition is provided comprising immunogenic polypeptides selected from the group consisting of human ?-lactalbumin, ?S1 casein, ?-casein and ?-casein.Type: GrantFiled: May 2, 2016Date of Patent: February 6, 2018Assignee: The Cleveland Clinic FoundationInventor: Vincent K. Tuohy
-
Patent number: 9879087Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: GrantFiled: January 4, 2016Date of Patent: January 30, 2018Assignee: SIAMAB THERAPEUTICS, INC.Inventors: Julie DeSander, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
-
Patent number: 9873734Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.Type: GrantFiled: November 5, 2012Date of Patent: January 23, 2018Assignee: GENENTECH, INC.Inventors: Sek Chung Fung, Kang Li, Zhengbin Yao
-
Patent number: 9857375Abstract: The present invention provides a novel cancer marker that is useful in the diagnosis of urothelial cancer. The present invention uses ubiquilin 2 as a cancer marker for urothelial cancer (renal pelvis cancer, ureteral cancer, and bladder cancer). Detection of ubiquilin 2 in a urine sample allows easy and accurate diagnosis of a possibility of urothelial cancer. The present invention is also applicable to the diagnosis of squamous cancer (esophageal cancer, cervical cancer, etc.).Type: GrantFiled: September 26, 2013Date of Patent: January 2, 2018Assignee: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITYInventors: Noboru Konishi, Keiji Shimada
-
Patent number: 9856324Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against disialoganglioside-GD2. The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to GD2. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.Type: GrantFiled: June 3, 2015Date of Patent: January 2, 2018Assignee: MabVax Therapeutics, Inc.Inventors: Wolfgang Scholz, Ritsuko Sawada
-
Patent number: 9850293Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Type: GrantFiled: April 4, 2015Date of Patent: December 26, 2017Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Lali K. Medina-Kauwe, Jessica Sims, Michael Taguaim, Chris Hanson, Xiaojiang Cui
-
Patent number: 9845350Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.Type: GrantFiled: January 21, 2016Date of Patent: December 19, 2017Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai